A new analysis of U.S. bariatric surgery data shows a notable decline in procedures as prescriptions for GLP‑1 weight-loss drugs and other nonsurgical programs have surged. Researchers used the ACS‑MBSAQIP national registry to track bariatric operations from 2020 through 2024 and found that overall case volumes peaked in 2022 before falling in the years that followed. Investigators say the pattern reflects growing patient and clinician interest in medical and programmatic alternatives to surgery.
Shifts in procedure types
The study also found changes in which surgeries are being performed. Sleeve gastrectomy — the once-dominant operation that reduces stomach size — remains common but has been performed less often as a share of total cases since 2020. By contrast, Roux‑en‑Y gastric bypass procedures have increased, especially as conversion operations for patients who previously had sleeves and need more weight loss or relief from complications. Other procedures, including adjustable gastric banding and various revisions, have shown modest rises as surgeons and patients choose more tailored approaches.
What’s driving the change
Experts point to wider availability of GLP‑1 receptor agonists (such as semaglutide and tirzepatide formulations) and expanded insurance- and clinic-based weight management services as major drivers. These medications have helped many people lose meaningful weight when diet and exercise alone failed, making nonsurgical treatment an attractive first option for some.
But clinicians emphasize that medications and surgery are different tools, not direct substitutes. Bariatric surgery has decades of data demonstrating durable weight loss and lasting improvements in diabetes, blood pressure, sleep apnea, mobility, and certain metabolic pathways. Minimally invasive laparoscopic techniques have shortened recovery times and hospital stays, making surgery less daunting than it once was.
Balancing benefits and risks
Physicians warn that the decline in surgical volume is neither wholly good nor bad — it depends on patient circumstances. For people with severe obesity and significant comorbidities (for example, a BMI of 35 or higher with diabetes or other health problems), surgery may offer far greater and more durable health benefits than medication alone. Some surgeons are concerned when patients forego surgery simply because taking a pill feels easier, without fully understanding the comparative long‑term outcomes.
At the same time, surgeons acknowledge that GLP‑1 drugs have genuinely changed the field. Many patients who failed multiple diets and older medications are now seeing clinically meaningful weight loss and health improvements from these drugs, which is a clear positive. In practice, clinicians say the best approach is individualized: for some, medication is sufficient; for others, surgery is the superior choice; and in many cases a combination or staged approach works best.
Making the right choice
Deciding between surgery, medication, or both requires a careful discussion with qualified providers who can assess obesity severity, medical history, the likelihood of remaining on medication long term, and personal preferences. Delaying effective treatment because patients wait for a “perfect” solution can lead to worsening diabetes and other complications — and some patients eventually require revision surgery after years of setbacks.
Bottom line: GLP‑1 drugs and expanded treatment options have reduced the number of bariatric surgeries in recent years, but surgery remains the most evidence-backed long‑term treatment for many people with severe obesity. The optimal plan depends on the individual — and should be made through shared decision-making with an experienced clinician.
